Filing Flows › GSK (GSK) › Q3 2026
GSK (GSK) Q3 2026 earnings results (third quarter 2026)
6-K filed Oct 28, 2026
GSK (GSK) reported revenue of $8.5B for the third quarter 2026 (Q3 2026) and +2% from the quarter before. Operating margin was 30.3%, net earnings $2.0B (23.6% of revenue).
GSK, Q3 2026: revenue $8.5B, operating margin 30.3%, net earnings $2.0B. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $8.5B | +2% | — |
| Gross profit | $6.3B | +2% | — |
| Operating profit | $2.6B | +439% | — |
| Net earnings | $2.0B | +363% | — |
What changed
Revenue was £8.5B in Q3 2026, up 2% from the previous quarter. HIV was the largest line at 25% of revenue.
Gross margin was 73.6%. Operating profit was £2.6B, a 30.3% margin. Net earnings were £2.0B. The effective tax rate was 12.7%.
Questions
What was GSK's revenue in the third quarter 2026?
GSK (GSK) reported revenue of $8.5B for the third quarter 2026 (Q3 2026) and +2% from the quarter before.
Was GSK profitable in the third quarter 2026?
Operating profit was $2.6B (30.3% of revenue) and net earnings $2.0B.
Source: GSK 6-K on SEC EDGAR.